

Figure 1




Figure 2

Control mAb

Anti-CD44

1001


S

Days after inoculation


3

Percent of mice with positive throat culture

Docket No. B0801/7237; Entitled: Prevention and Treatment of Streptococcal and Staphylococcal Infection; Inventors: Wessels et al.



mAb treatment: Control



Anti-CD44

Docket No. B0801/7237; Entitled: Prevention and Treatment of Streptococcal and Staphylococcal Infection; Inventors: Wessels et al.




Figure 5

Docket No. B0801/7237; Entitled: Prevention and Treatment of Streptococcal and Staphylococcal Infection; Inventors: Wessels et al.




Figure 6

Docket No. B0801/7237; Entitled: Prevention and Treatment of Streptococcal and Staphylococcal Infection; Inventors: Wessels et al.





Figure 7

Docket No. B0801/7237; Entitled: Prevention and Treatment of Streptococcal and Staphylococcal

Infection; Inventors: Wessels et al.



100 80 60 40 20 1 2 3 Days after challenge HA




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13